Liven Pharma Limited has marked a milestone by executing its first export order to the Arab region. Originally booked in the prior year, the order has now been fully delivered, signaling Liven’s initiation into global pharmaceutical trade. The company simultaneously announced plans to pursue a Rs. 200 million rights issue to bolster its balance sheet and support expansion initiatives.
In disclosure to the Pakistan Stock Exchange, the company stated that the export order has now been fulfilled. Under the rights issue plan, Liven Pharma will issue 20 million ordinary shares at Rs. 10 per share, representing roughly 21.5% of its existing paid-up capital—equating to 21.496 rights shares for every 100 existing shares. The capital raise is intended to strengthen working capital, scale production capacity, enhance product lines, and sustain its export ambitions.
“Completing this first export to the Arab region is an affirmation of our quality standards and export capabilities,” said a Liven Pharma executive. “With the support of this rights issue, we will accelerate growth, expand product reach, and deepen our presence in international markets.” The company, incorporated in 1991 and converted into a public limited company in 1992, primarily manufactures finished pharmaceuticals and allied products for domestic and export markets.
The export breakthrough is especially meaningful in light of Pakistan’s pharmaceutical industry’s historical dependence on imports and limited export penetration. With over 90% of raw materials imported, Liven’s success may inspire confidence in the local industry’s capacity to meet global standards. The company’s leadership sees this as a foundational step toward becoming an export‑oriented pharma champion—one that can support foreign exchange generation, technology adoption, and greater competitiveness on the global stage.
